Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
| Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
| Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
| Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
| Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
| Cerus Corporation, Medical Equipment, Deal Details | 11 | 15 |
| Partnerships | 11 | 1 |
| Cerus Terminates Licensing Agreement With BioOne | 11 | 1 |
| Cerus Enters into Agreement with Haemonetics | 12 | 1 |
| Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan | 13 | 1 |
| Cerus Enters into Co-Marketing Agreement with Biomedica Foscama | 14 | 1 |
| Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma | 15 | 1 |
| Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma | 16 | 1 |
| Cerus Enters Into Distribution Agreement With Ilex Biotech | 17 | 1 |
| Cerus Enters Into Agreement With CSL | 18 | 1 |
| Equity Offering | 19 | 1 |
| Cerus Plans to Raise USD70 Million in Public Offering of Shares | 19 | 1 |
| Cerus Prices Public Offering of Shares for USD70 Million | 20 | 2 |
| Cerus Completes Public Offering Of Shares For US$40.3 Million | 22 | 2 |
| Cerus Completes Underwritten Public Offering Of US$21 Million | 24 | 2 |
| Cerus Corporation - Key Competitors | 26 | 1 |
| Key Employees | 27 | 1 |
| Locations And Subsidiaries | 28 | 1 |
| Head Office | 28 | 1 |
| Other Locations &Subsidiaries | 28 | 1 |
| Recent Developments | 29 | 1 |
| Financial Announcements | 29 | 1 |
| Aug 04, 2016: Cerus Reports Second Quarter 2016 Results | 29 | 2 |
| May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results | 31 | 2 |
| Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results | 33 | 2 |
| Nov 05, 2015: Cerus Reports Third Quarter 2015 Results | 35 | 2 |
| Aug 06, 2015: Cerus Reports Second Quarter 2015 Results | 37 | 2 |
| May 05, 2015: Cerus Reports First Quarter 2015 Results | 39 | 2 |
| Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results | 41 | 2 |
| Corporate Communications | 43 | 1 |
| Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation s Chief Commercial Officer | 43 | 1 |
| Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region | 44 | 1 |
| Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation s New Chief Medical Officer | 45 | 1 |
| Product News | 46 | 1 |
| Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma | 46 | 1 |
| Mar 15, 2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA s Revised Guidance Document on Bacterial Safety Standards for Platelets | 47 | 1 |
| Mar 09, 2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology | 48 | 1 |
| Feb 09, 2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma | 49 | 1 |
| Jan 14, 2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease | 50 | 1 |
| Jan 05, 2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma | 51 | 1 |
| Dec 10, 2015: Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma | 52 | 1 |
| Dec 07, 2015: Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma | 53 | 1 |
| Nov 02, 2015: Cerus Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma | 54 | 1 |
| Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components | 55 | 1 |
| Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets | 56 | 1 |
| Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden s Largest Blood Product Supplier | 57 | 1 |
| Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System | 58 | 1 |
| Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint | 59 | 1 |
| Product Approvals | 60 | 1 |
| Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma | 60 | 1 |
| Clinical Trials | 61 | 1 |
| Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets | 61 | 1 |
| Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint | 62 | 1 |
| Other Significant Developments | 63 | 1 |
| Oct 10, 2016: Cerus Announces that Hemolife Fundaci n Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System | 63 | 1 |
| Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma | 64 | 2 |
| Oct 21, 2015: Cerus Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits | 66 | 1 |
| Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma | 67 | 1 |
| Appendix | 68 | 1 |
| Methodology | 68 | 1 |
| About GlobalData | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 68 | 1 |